Loading stock data…
ARCT
$7.16+0.04 (+0.56%)
After Hours$7.16+0.00 (+0.00%)· Last close Jun 9
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcturus Therapeutics Holdings Inc. in the Healthcare sector is trading at $7.16 with a market capitalization of $216M. Wall Street consensus targets $19.89 (9 analysts), implying a +177.8% move over the next 12 months. The stock is currently near its 52-week low of $5.85, remaining 29.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +177.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$7.16
Potential Downside
0%
Whystock Fair Value$7.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a li...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$216.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.11%
Volume
Today's trading volume
242,010
Recent News
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York. Payne described Arcturus as a “next generation messen
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary
Moby summary of Arcturus Therapeutics Holdings Inc.'s Q1 2026 earnings call
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics Q1 Earnings Call Highlights
Arcturus Therapeutics (NASDAQ:ARCT) executives highlighted progress in two rare-disease clinical programs and outlined a strengthened cash runway during the company’s first-quarter 2026 earnings call, while also discussing ongoing partner activity for its self-amplifying mRNA COVID-19 vaccine in Jap
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +9.70% and +1.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?